1. Home
  2. FUSB vs IMUX Comparison

FUSB vs IMUX Comparison

Compare FUSB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

N/A

Current Price

$13.53

Market Cap

79.8M

Sector

Finance

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.52

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
IMUX
Founded
1952
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.8M
85.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FUSB
IMUX
Price
$13.53
$0.52
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$6.00
AVG Volume (30 Days)
9.3K
1.5M
Earning Date
01-26-2026
02-14-2026
Dividend Yield
2.05%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$36,068,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.30
$0.54
52 Week High
$14.79
$1.39

Technical Indicators

Market Signals
Indicator
FUSB
IMUX
Relative Strength Index (RSI) 49.66 30.10
Support Level $12.90 $0.55
Resistance Level $13.71 $0.60
Average True Range (ATR) 0.30 0.04
MACD -0.05 -0.00
Stochastic Oscillator 41.47 2.23

Price Performance

Historical Comparison
FUSB
IMUX

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: